Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Open-label Study of Adavosertib (AZD1775) in Japanese Patients With Advanced Solid Tumours
jRCT2080225236Phase 1Suspended
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in Nonhematologic neoplasms, sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of adavosertib, Pharmacokinetics of adavosertib and 1 more. Started Jun 2020; status: suspended.
02
Drugs
adavosertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080225236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225236.